Peter Schmid is a founding partner of Conditor Capital. Peter has c. 30 years of experience in private equity. Most recently, he was chairman of PE investment committee of Ninety One (formerly Investec Asset Management). Previously, Peter led Private Equity business of Actis (London based PE firm with c. $15B AUM and 12 offices around the world) where he was a partner for last twelve years. He was involved in raising and deploying several private equity funds for Actis globally. Earlier, Peter was managing partner of Ethos Private Equity based in South Africa where he spent eleven years. Peter is a non-executive director of South Africa’s listed business Barloworld
Education:
- University of Witwatersrand
- Chartered Accountant
Sachin Korantak is founding partner of Conditor Capital. Sachin brings a wealth of senior level experience in private equity (PE) as an investor, operating partner, and a board member. His PE experience spans the whole investment lifecycle –from origination to value creation and board roles. His experience spans across Healthcare, Business Services, Renewable Energy, Industrials, Consumer, and Fin-Tech / SaaS sectors. Previously he has been a CEO, led performance transformations in Europe and US, and was a strategy consultant at McKinsey earlier in his career. Sachin is a true global citizen, with operating experience in Europe, USA, Asia, Africa, and Latin America. He has lived in four countries and speaks four languages.
Education:
- MBA from Ross Business School, Ann Arbor, Michigan
- Bachelor of Engineering from University of Pune
Board Member – Managing Director at Janic Capital
Adriaan is the Managing Director of Janic Capital, a permanent capital vehicle investing for the long term in high-growth private businesses across a variety of sectors and growth stages. Adriaan was previously part of Ninety One’s (formerly Investec Asset Management) private equity team where he focused on growth equity and mid-market buyout investments, and represented the Ninety One PE funds on the board of directors of several portfolio companies. Adriaan holds a MFin from the
University of Cambridge, an MSc in International Business from Edinburgh University and a BCom degree (Hons.) in Economics from Stellenbosch University.
Alistair is a seasoned pharmaceutical services executive with more than 25 years of experience in the industry, across manufacturing, consultancy, business and corporate development, data management, clinical and commercial operations. Until April 2022 Alistair was CEO of the industry leading, integrated CRO Syneos Health Inc (NASDAQ, SYNH). a role which he held for 6 years. Syneos was the result of a combination of inVentiv Health and INC Research in 2017, of which Alistair was CEO. Alistair led the merger that formed Syneos, bringing together approximately 29,000 employees serving customers in 110 countries with innovative, end-to-end solutions to accelerate their clinical development and commercialisation timelines. Prior to becoming CEO of INC Research, Alistair led multiple functions including Global Business Development and Marketing, Alliances Development and Delivery, Global Oncology, and Clinical Development Services.
Alistair has served as Chair of ACRO, the Association of Clinical Research Organisations, having been on its board for approximately seven years, and is Non-Executive Director of the Medicines Discovery Catapult.
Alistair received his Masters degree from Cranfield University, and Batchelors degree from Plymouth University.
Experienced senior executive and entrepreneur with many years of experience in drug discovery, company formation, financing, growth and exit. Neil has previously founded both biotech and contract research organisations. As founder of KWS BioTest, Neil grew a CRO from inception to sale, providing both scientific and commercial leadership. He has also been Director of Immunology at Charles River Laboratories, Director of Strategic Alliances at the Elizabeth Blackwell Institute for Health Research and Chairman of the BSI. His commercial experience is founded on a strong scientific track record as Professor of Immunology at the University of Bristol. Neil is passionate about supporting entrepreneurs to build businesses that make a difference to patients’ lives.
Robin Brown is the Chairman of Nexus BioQuest and brings experience from nearly every sector of private healthcare innovation. He has held senior positions in biotech, big pharma, contract research and venture capital/private equity investment. Robin is currently Chairman of the Medicines Discovery Catapult and is a committee member of the UCL Technology Fund managed by Albion Capital. Recently he was CEO of KWS Biotest until its acquisition by Charles River Laboratories in 2018. Previously he spent eight years as a venture partner with Advent International. His biotechnology experience, while living in Belgium, was as CSO of Devgen (acquired by Syngenta) and Galapagos.
Will is the Chief Executive Officer of Nexus BioQuest and brings over 20 years experience working in commercial science positions at companies including Zeneca, Syngenta, KWS BioTest, Charles River and Nexus BioQuest. Originally trained as a molecular biologist he has held a wide range of positions from Research Scientist, Team Leader, British Army Officer, Project Manager, Chief Operations Officer and Site Director.He holds both a BSc in Biotechnology and Master of Business Administration with a specialism in innovation. The main elements brought to Nexus BioQuest include experience growing a start up to acquisition, leadership in complex environments and projects, fiduciary responsibility to create a stable business and management of high growth operations.